<DOC>
	<DOCNO>NCT01787994</DOCNO>
	<brief_summary>This open label , dual cohort study evaluate safety , tolerability immunogenicity redirect CD4+ T cell HIV subject .</brief_summary>
	<brief_title>Redirected MazF‐CD4 Autologous T Cells HIV Gene Therapy</brief_title>
	<detailed_description />
	<criteria>1 . HIV1 infection , document rapid HIV test FDAapproved HIV1 enzyme chemiluminescence immunoassay ( E/CIA ) test kit confirm Western blot time prior study entry . Alternatively , rapid HIV test FDAapproved HIV1 enzyme chemiluminescence immunoassay ( E/CIA ) test kit available , two HIV1 RNA value &gt; 2000 copies/mL least 24 hour apart perform laboratory CLIA certification , equivalent , may use document infection . 2 . Antiretroviral medication Cohort 1 : Subjects HAART ( change treatment within 4 week study entry ) least 3 month . Subjects HAART ( change treatment within 4 week study entry ) least 3 month . 3 . Plasma HIV viremia Cohort 1 : HIV‐1‐positive men woman &gt; 18 year age HIV‐1‐RNA level undetectable ultrasensitive HIV PCR Abbott assay screen . Also eligible subject HIV‐1 RNA &lt; 400 copies/mL ; however , HIV‐1 RNA must &lt; 50 copies/mL within 60 day prior study entry base Abbott assay . Subjects intermittent isolate episode detectable low level viremia ( &gt; 50 &lt; 1,000 copy RNA/mL ; blip ) eligible . There least 2 documented HIV‐1 RNA assay , one drawn &gt; 3 month study entry , one drawn &lt; 3 month study entry . Cohort 2 : HIV1positive men woman &gt; 18 year age HIV1RNA level undetectable ultrasensitive HIV PCR assay screen . Note : Due sensitivity issue use Roche Assay fact control HIV testing technique prior enrollment , decide consider subject HIV1 RNA &lt; 400 copies/mL ; however , HIV1 RNA must undetectable within 60 day prior study entry base ultrasensitive HIV PCR assay . Subjects intermittent isolate episode detectable low level viremia ( &gt; 50 &lt; 1,000 copy RNA/mL ; blip ) eligible . There least 2 documented HIV1 RNA assay : one drawn &gt; 3 month study entry , one drawn &lt; 3 month study entry . 4 . CD4 count Cohort 1 : Subjects CD4 count &gt; 350 cells/mm3 . Cohort 2 : Subjects CD4 count least 450 cells/mm3 screening . Note : CD4 nadir Cohort 2 must 200 cells/mm3 . 5 . Adequate venous access contraindication leukapheresis . 6 . Laboratory value obtain within 60 day prior entry . Hemoglobin : ≥ 10.0 ( male ) ; ≥ 9.5 ( female ) g/dL Absolute neutrophil count ( ANC ) : ≥ 1000/mm3 Platelet count : ≥ 75,000/mm3 Serum creatinine : ≤ 1.5 mg/dL ( 133μ mol/L ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) : ≤ 2.5 time upper limit normal ( ULN ) . 7 . Subjects must willing comply study‐mandated evaluation . Rectal biopsy procedure optional . 8 . Be male female , 18 year age old . 9 . Ability willingness subject provide inform consent . 10 . Have Karnofsky Performance Score 70 high . 1 . No history opportunistic infection neoplasm . 2 . Concomitant acute chronic hepatitis B ( surface antigen positive ) hepatitis C infection . If HCV antibody test positive , HCV RNA test performed . If HCV test ( antibody RNA ) positive , subject exclude study . If HCV antibody test positive , HCV RNA test negative , subject enroll . Results obtain 30 day prior screen . 3 . History cancer malignancy , exception successfully treat basal cell squamous cell carcinoma skin . 4 . 4.2.4 History feature physical examination indicative active unstable cardiac disease hemodynamic instability . 5 . History feature physical examination indicative bleeding diathesis . 6 . Have previously treat HIV experimental vaccine within 6 month prior screen , previous gene therapy use integrate vector . 7 . Use chronic corticosteroid , hydroxyurea , immunomodulating agent ( e.g. , interleukin‐2 , interferon‐alpha ‐gamma , granulocyte colony stimulate factor , etc . ) within 30 day prior study entry . 8 . Breastfeeding , pregnant , unwilling use acceptable method birth control . 9 . Use aspirin , dipyrdamole , warfarin medication likely affect platelet function aspect blood coagulation 2week period prior leukapheresis . 10 . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . 11 . Serious illness require systemic treatment and/or hospitalization within 30 day prior study entry . 12 . Asymptomatic abnormal baseline serum chemistry elevation . Note : Asymptomatic baseline serum chemistry elevation total indirect bilirubin subject receive atazanavir indinavir exclusionary . Asymptomatic baseline serum chemistry elevation LFTs , lipase creatinine due HAART medication exclusionary , opinion investigator , abnormality attributable intrinsic hepatorenal disease . Such elevation must due HAART . 13 . Receipt vaccination within 30 day prior study entry . 14 . Have allergy hypersensitivity study product excipients ( human serum albumin , DMSO Dextran 40 ) . 15 . For Cohort 2 : CD4 nadir 200 cells/mm3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>